Skip to main content

Advertisement

SpringerLink
Log in

Relation of urinary stone disease with androgenetic alopecia and serum testosterone levels

  • Original Paper
  • Published:
Urolithiasis Aims and scope Submit manuscript

Abstract

We aimed to investigate the relationship among urinary stone disease, androgenetic alopecia (AGA), and serum testosterone (T) levels. Between January 2008 and November 2015, we retrospectively investigated the biochemical parameters and anthropometric characteristics (height and weight) of 200 patients who had urinary tract stones. For the control group, we selected at random 168 participants who had no history of urolithiasis. Demographic data, such as participants’ age, body mass index (BMI), hypertension (HT), diabetes mellitus (DM), baldness pattern, and serum T level were recorded. All participants were male, over 18 and under 60 years of age. We determined that risk of urolithiasis increased 1.3-fold in patients with vertex pattern alopecia and 2.1-fold in patients with total alopecia compared with those with no hair loss. In the severe balding Groups (Group III and Group IV), presence of testosterone deficiency was more frequent in patients with urinary stone disease (P = 0.041, OR = 2.38). Although in the non- balding and mild balding Groups (Group I and Group II), presence of testosterone deficiency was also more frequent in patients with urinary stone disease, a statistically significant difference was not seen. Significantly, we found that the presence of testosterone deficiency was more frequent in patients with urinary stone disease and who had severe AGA.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Curhan GC (2007) Epidemiology of stone disease. Urol Clin North Am 34:287–293

    Article  PubMed  PubMed Central  Google Scholar 

  2. Lee YH, Huang WC, Chiang H et al (1996) Testesterone enhances whereas estrogen inhibits calcium oxalate stone formation in ethylene glycol treated rats. J Urol 156:502–505

    Article  CAS  PubMed  Google Scholar 

  3. Iguchi M, Takamura C, Umekawa T et al (1999) Inhibitory effects of female sex hormones on urinary stone formation in rats. Kidney Int 56:479–485

    Article  CAS  PubMed  Google Scholar 

  4. Scales CD Jr, Curtis LH, Norris RD et al (2007) Changing gender prevalence of stone disease. J Urol 177:979–982

    Article  PubMed  Google Scholar 

  5. Otunctemur A, Ozbek E, Cakir SS et al (2015) Urolithiasis is associated with low serum testosterone levels in men. Arch Ital Urol Androl 87(1):83–86

    Article  PubMed  Google Scholar 

  6. Taylor EN, Stampfer MJ, Curhan GC (2005) Obesity, weight gain, and the risk of kidney stones. JAMA 293:455–462

    Article  CAS  PubMed  Google Scholar 

  7. Taylor EN, Stampfer MJ, Curhan GC (2005) Diabetes mellitus and the risk of nephrolithiasis. Kidney Int 68:1230–1235

    Article  PubMed  Google Scholar 

  8. Curhan GC et al (1998) Body size and risk of kidney stones. J Am Soc Nephrol 9:1645–1652

    CAS  PubMed  Google Scholar 

  9. Yassin AA, Saad F, Gooren LJ (2008) Metabolic syndrome, testosterone deficiency and erectile dysfunction never come alone. Andrologia 40:259–264

    Article  CAS  PubMed  Google Scholar 

  10. Kupelian V, Hayes FJ, Link CL et al (2008) Inverse association of testosterone and the metabolicsyndrome in men is consistent across race and ethnic groups. J Clin Endocrinol Metab 93:3403–3410

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Inui S, Itami S (2011) Molecular basis of androgenic alopecia: from androgen to paracrine mediators through dermal papilla. J Dermatol Sci 61:1–6

    Article  CAS  PubMed  Google Scholar 

  12. Amoretti A, Laydner H, Bergfeld W et al (2013) Androgenetic alopecia and risk of prostate cancer: a systematic review and meta-analysis. J Am Acad Dermatol 68:937–943

    Article  PubMed  Google Scholar 

  13. Ellis JA, Stebbing M, Harrap SB (2001) Polymorphism of the androgen receptor gene is associated with male pattern baldness. J Invest Dermatol 116:452–455

    Article  CAS  PubMed  Google Scholar 

  14. Arias-Santiago S, Arrabal-Polo MA, Buendía-Eisman A et al (2012) Androgenetic alopecia as an early marker of benign prostatic hyperplasia. J Am Acad Dermatol 66(3):401–408

    Article  PubMed  Google Scholar 

  15. Dogramaci AC, Balci DD, Balci A et al (2009) Is androgenetic alopecia a risk for atherosclerosis? J Eur Acad Dermatol Venereol 23:673–677

    Article  CAS  PubMed  Google Scholar 

  16. Trabert B, Sigurdson AJ, Sweeney AM et al (2011) Baldness, acne and testicular germ cell tumors. Int J Androl 34:59–67

    Article  Google Scholar 

  17. Lai JJ, Chang P, Lai P et al (2012) The role of androgen and androgen receptor in skin-related disorders. Arch Dermatol Res 304:499–510

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Resorlu M, Sancak EB, Uysal F et al (2016) The association of urolithiasis and androgenetic alopecia. Ren Fail 38(1):84-88. doi:10.3109/0886022X.2015.1096729

    Article  PubMed  Google Scholar 

  19. Norwood OT (1975) Male pattern baldness: classification and incidence. South Med J 68:1359–1365

    Article  CAS  PubMed  Google Scholar 

  20. Huang PL (2009) A comprehensive definition for metabolic syndrome. Dis Model Mech 2:231–237

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Severi G, Sinclair R, Hopper JL et al (2003) Androgenetic alopecia in men aged 40–69 years: prevalence and risk factors. Br J Dermatol 149:1207–1213

    Article  CAS  PubMed  Google Scholar 

  22. Soundararajan P, Mahesh R, Ramesh T, Begum VH (2006) Effect of Aerva lanata on calcium oxalate urolithiasis in rats. Indian J Exp Biol 44(12):981–986

    CAS  PubMed  Google Scholar 

  23. Fan J, Chandhoke PS, Grampsas SA (1999) Role of sex hormones in experimental calcium oxalate nephrolithiasis. J Am Soc Nephrol Suppl 14:S376–S380

    Google Scholar 

  24. Yagisawa T, Ito F, Osaka Y, Amano H, Kobayashi C et al (2001) The influence of sex hormones on renal osteopontin expression and urinary constituents in experimental urolithiasis. J Urol 166:1078–1082

    Article  CAS  PubMed  Google Scholar 

  25. Fan J, Glass MA, Chandhoke PS (1998) Effect of castration and finasteride on urinary oxalate excretion in male rats. Urol Res 26(1):71–75

    Article  CAS  PubMed  Google Scholar 

  26. Griffin JE, Wilson JD (1989) The androgen resistance syndrome: 5α-reductase deficiency, testicular feminization, and related disorders. In: Scriver CR, Beaudet AL, Sly WS, DV (eds) The metabolic basis of inherited disease. McGraw-Hill, New York, pp 1919–1944

    Google Scholar 

  27. Hibberts NA, Howell AE, Randall VA (1998) Balding hair follicle dermal papilla cells contain higher levels of androgen receptors than those from non-balding scalp. J Endocrinol 156(1):59–65

    Article  CAS  PubMed  Google Scholar 

  28. Hillmer AM, Hanneken S, Ritzmann S et al (2005) Genetic variation in the human androgen receptor gene is the major determinant of common early-onset androgenetic alopecia. Am J Hum Genet 77(1):140–148

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Dusková M, Cermákova I, Hill M, Vanková M, Samalíková P, Stárka L (2004) What may be the markers of the male equivalent of polycystic ovary syndrome? Physiol Res 53:287–294

    PubMed  Google Scholar 

  30. Oh BR, Kim SJ, Moon JD, Kim HN, Kwon DD, Won YH et al (1998) Association of benign prostatic hyperplasia with male pattern baldness. Urology 51:744–748

    Article  CAS  PubMed  Google Scholar 

  31. Chen W, Yang CC, Chen GY, Wu MC, Sheu HM, Tzai TS (2004) Patients with a large prostate show a higher prevalence of androgenetic alopecia. Arch Dermatol Res 296:245–249

    Article  PubMed  Google Scholar 

  32. Matilainen V, Koskela P, Keina¨nen-Kiukaanniemi S (2000) Early androgenetic alopecia as a marker of insulin resistance. Lancet 356:1165–1166

    Article  CAS  PubMed  Google Scholar 

  33. Matilainen V, Laakso M, Hirsso P, Koskela P, Rajala U, Keina¨nen-Kiukaanniemi S (2003) Hair loss, insulin resistance, and heredity in middle-aged women: a population-based study. J Cardiovasc Risk 10:227–231

    Article  PubMed  Google Scholar 

  34. Klemp P, Peters K, Hansted B (1989) Subcutaneous blood flow in early male pattern baldness. J Invest Dermatol 92:725–726

    Article  CAS  PubMed  Google Scholar 

  35. Goldman BE, Fisher DM, Ringler SL (1996) Transcutaneous PO2 of the scalp in male pattern baldness: a new piece to the puzzle. Plast Reconstr Surg 97:1109–1116

    Article  CAS  PubMed  Google Scholar 

  36. Arias-Santiago S, Gutierrez-Salmeron MT, Castellote-Caballero L et al (2010) Androgenetic alopecia and cardiovascular risk factors in men and women: a comparative study. J Am Acad Dermatol 63:420–429

    Article  PubMed  Google Scholar 

Download references

Acknowledgement

We acknowledge that all authors have made substantial contribution to the work, and all have read and approved the final manuscript. The manuscript is an original work, being under consideration by neither another journal nor electronic publication, and has not been previously published. We do also affirm that there was no source of extra-institutional funding, none of the authors has direct or indirect commercial financial incentive associating with publishing the article, and no funding agreement limits our ability to complete and publish the study.

Author information

Authors and Affiliations

  1. Department of Urology, Okmeydani Training and Research Hospital, Sisli, 34384, Istanbul, Turkey

    Emre Can Polat, Alper Otunctemur & Emin Ozbek

  2. Department of Urology, Derince Training and Research Hospital, Kocaeli, İzmit, Turkey

    Levent Ozcan

Authors
  1. Emre Can Polat
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Levent Ozcan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alper Otunctemur
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Emin Ozbek
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Emre Can Polat.

Ethics declarations

Financial disclosure

The authors declared that this study has received no financial support.

Conflict of interest

Emre Can Polat declares that has no conflict of interest. Levent Ozcan declares that has no conflict of interest. Alper Otunctemur declares that has no conflict of interest. Emin Ozbek declares that has no conflict of interest. Emre Can Polat read and approved this article. Levent Ozcan read and approved this article. Alper Otunctemur read and approved this article. Emin Ozbek read and approved this article.

Ethical approval

Ethical approval Date: 3.11.2010. Ethical approval Number: B.10.4.İSM.04.34.61.12.900. We declare that our manuscript entitled with ‘Relation of urinary stone disease with androgenetic alopecia and serum testosterone levels’. We must also state that the protocol for the research project has been approved by a suitably constituted Ethics Committee of the institution within which the work was undertaken and that it conforms to the provisions of the Declaration of Helsinki (as revised in Tokyo 2004). All participants signed an informed consent before being enrolled in the study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Polat, E.C., Ozcan, L., Otunctemur, A. et al. Relation of urinary stone disease with androgenetic alopecia and serum testosterone levels. Urolithiasis 44, 409–413 (2016). https://doi.org/10.1007/s00240-016-0888-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00240-016-0888-3

Keywords

Search

Navigation